Our results demonstrate that treatment with either quiescent or activated CD4/CD8 T cells or activated CD11b+ cells does not significantly increase infarct volume when administered 24 h prior to the onset of stroke in splenectomized mice. This evidence concerns the gene CD4 and stroke disorder.